Integrative Analysis Identifies a Novel AXL–PI3 Kinase–PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer
暂无分享,去创建一个
Jing Wang | J. Heymach | L. Byers | Michelle D. Williams | M. Story | R. Meyn | C. Pickering | J. Myers | B. Beadle | Y. Liu | H. Skinner | U. Giri | Youhong Fan | Li Shen | Liangpeng Yang | Manish Kumar | S. Yoo | D. Molkentine | J. Heymach | M. Williams
[1] Jing Wang,et al. Proteomic Profiling Identifies PTK2/FAK as a Driver of Radioresistance in HPV-negative Head and Neck Cancer , 2016, Clinical Cancer Research.
[2] J. Sosman,et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2016, Cell.
[3] G. Freeman,et al. Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer. , 2016, Cancer research.
[4] Ju-Seog Lee,et al. PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma , 2016, Oncotarget.
[5] Jing Wang,et al. Epithelial–Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma , 2016, Clinical Cancer Research.
[6] J. McQuade,et al. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. , 2016, Cancer discovery.
[7] Jaime Rodriguez-Canales,et al. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition , 2015, Clinical Cancer Research.
[8] Michael Peyton,et al. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. , 2015, Cancer discovery.
[9] N. Matsumura,et al. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer , 2015, British Journal of Cancer.
[10] R. Salgia,et al. AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma , 2015, Clinical Cancer Research.
[11] A. Jemal,et al. Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.
[12] Steven J. M. Jones,et al. Comprehensive genomic characterization of head and neck squamous cell carcinomas , 2015, Nature.
[13] K. Ang,et al. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] H. Kohrt,et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.
[15] P. Hegde,et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.
[16] R. Emerson,et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.
[17] Sue S Yom,et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] K. Ang,et al. Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] I. Wistuba,et al. ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism. , 2014, The Journal of clinical investigation.
[20] Antoni Ribas,et al. Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma , 2014, Clinical Cancer Research.
[21] R. Weichselbaum,et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. , 2014, The Journal of clinical investigation.
[22] R. Hill,et al. Cancer stem cells, the epithelial to mesenchymal transition (EMT) and radioresistance: potential role of hypoxia. , 2013, Cancer letters.
[23] Michael Peyton,et al. An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance , 2012, Clinical Cancer Research.
[24] Michael Peyton,et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. , 2012, Cancer discovery.
[25] K. Ang,et al. TP53 Disruptive Mutations Lead to Head and Neck Cancer Treatment Failure through Inhibition of Radiation-Induced Senescence , 2011, Clinical Cancer Research.
[26] G. Robert,et al. Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells , 2011, Oncotarget.
[27] D. Kufe,et al. PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine , 2011, Journal of immunotherapy.
[28] E John Wherry,et al. T cell exhaustion , 2011 .
[29] A. Garden,et al. DNA Repair Biomarker Profiling of Head and Neck Cancer: Ku80 Expression Predicts Locoregional Failure and Death following Radiotherapy , 2011, Clinical Cancer Research.
[30] P. Tien,et al. PD‐1 and PD‐L1 upregulation promotes CD8+ T‐cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients , 2011, International journal of cancer.
[31] K. Ang,et al. Human papillomavirus and survival of patients with oropharyngeal cancer. , 2010, The New England journal of medicine.
[32] W. Isaacs,et al. Human prostate‐infiltrating CD8+ T lymphocytes are oligoclonal and PD‐1+ , 2009, The Prostate.
[33] S. Rosenberg,et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. , 2009, Blood.
[34] R. Weichselbaum,et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. , 2009, Blood.
[35] J. Bussink,et al. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. , 2008, The Lancet. Oncology.
[36] J. Manola,et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. , 2007, The New England journal of medicine.
[37] Philip J. R. Goulder,et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression , 2006, Nature.
[38] K. Camphausen,et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy , 2006, The Journal of experimental medicine.
[39] Lieping Chen,et al. Interferon regulatory factor‐1 is prerequisite to the constitutive expression and IFN‐γ‐induced upregulation of B7‐H1 (CD274) , 2006, FEBS letters.
[40] Robert C. Rose,et al. Local Radiation Therapy of B16 Melanoma Tumors Increases the Generation of Tumor Antigen-Specific Effector Cells That Traffic to the Tumor1 , 2005, The Journal of Immunology.
[41] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.